Abstract Neoadjuvant radiotherapy and chemotherapy combined with surgery is the standard treatment for patients with locally advanced esophageal cancer, which has been widely applied in clinical practice. Clinical efficacy has also been recognized by clinicians. However, even after the completion of neoadjuvant radiotherapy and subsequent surgical treatment, some patients still have local regional recurrence or distant metastasis in a short period of time. Among them, distant metastasis has become the main failure mode of patients undergoing surgery after neoadjuvant radiotherapy and chemotherapy, indicating that this treatment remains to be further improved. Based on the experience of patients with rectal cancer benefiting from total neoadjuvant therapy, the feasibility and implementation of total neoadjuvant therapy for locally advanced esophageal cancer were discussed in this article.
Wen Jingyuan,Shen Wenbin,Zhu Shuchai. Exploration of feasible total neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma[J]. Chinese Journal of Radiation Oncology, 2023, 32(1): 65-69.
Wen Jingyuan,Shen Wenbin,Zhu Shuchai. Exploration of feasible total neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma[J]. Chinese Journal of Radiation Oncology, 2023, 32(1): 65-69.
[1] Oppedijk V, van der Gaast A, van Lanschot JJ, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials[J]. J Clin Oncol, 2014,32(5):385-391. DOI: 10.1200/JCO.2013.51.2186. [2] Liu S, Wen J, Yang H, et al.Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010[J]. Eur J Cancer, 2020,138:113-121. DOI: 10.1016/j.ejca.2020.08.002. [3] Kurumi H, Isomoto H.Current topics in esophageal squamous cell carcinoma[J]. Cancers (Basel), 2020,12(10): 2898. DOI: 10.3390/cancers12102898. [4] Ma K, Yang Y, Wang S, et al.Stage selection for neoadjuvant radiotherapy in non-cervical esophageal cancer: a propensity score-matched study based on the SEER database[J]. Thorac Cancer, 2018,9(9):1111-1120. DOI: 10.1111/1759-7714.12794. [5] Thakur B, Devkota M, Chaudhary M.Management of locally advanced esophageal cancer[J]. JNMA J Nepal Med Assoc, 2021,59(236):409-416. DOI: 10.31729/jnma.4299. [6] Kumar T, Pai E, Singh R, et al.Neoadjuvant strategies in resectable carcinoma esophagus: a meta-analysis of randomized trials[J]. World J Surg Oncol, 2020,18(1):59. DOI: 10.1186/s12957-020-01830-x. [7] Mayanagi S, Irino T, Kawakubo H, et al.Neoadjuvant treatment strategy for locally advanced thoracic esophageal cancer[J]. Ann Gastroenterol Surg, 2019,3(3):269-275. DOI: 10.1002/ags3.12243. [8] Yamasaki M, Yasuda T, Yano M, et al.Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003)[J]. Ann Oncol, 2017,28(1):116-120. DOI: 10.1093/annonc/mdw439. [9] Shiraishi O, Yamasaki M, Makino T, et al.Feasibility of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil versus adriamycin, cisplatin, and 5-fluorouracil for resectable advanced esophageal cancer[J]. Oncology, 2017,92(2):101-108. DOI: 10.1159/000452765. [10] Wang T, Yu J, Liu M, et al.The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies[J]. Drug Des Devel Ther, 2019,13:539-553. DOI: 10.2147/DDDT.S189514. [11] Petrelli F, Ghidini M, Barni S, et al.Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis[J]. Gastric Cancer, 2019,22(2):245-254. DOI: 10.1007/s10120-018-0901-3. [12] Hoeppner J, Lordick F, Brunner T, et al.ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286)[J]. BMC Cancer, 2016,16:503. DOI: 10.1186/s12885-016-2564-y. [13] Anderegg M, van der Sluis PC, Ruurda JP, et al. Preoperative chemoradiotherapy versus perioperative chemotherapy for patients with resectable esophageal or gastroesophageal junction adenocarcinoma[J]. Ann Surg Oncol, 2017,24(8):2282-2290. DOI: 10.1245/s10434-017-5827-1. [14] van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. N Engl J Med, 2012,366(22):2074-2084. DOI: 10.1056/NEJMoa1112088. [15] Ando N, Kato H, Igaki H, et al.A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907)[J]. Ann Surg Oncol, 2012,19(1):68-74. DOI: 10.1245/s10434-011-2049-9. [16] Eyck BM, van Lanschot J, Hulshof M, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial[J]. J Clin Oncol, 2021,39(18):1995-2004. DOI: 10.1200/JCO.20.03614. [17] Yang H, Liu H, Chen Y, et al.Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial[J]. J Clin Oncol, 2018,36(27):2796-2803. DOI: 10.1200/JCO.2018.79.1483. [18] Yang H, Liu H, Chen Y, et al.Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial[J]. JAMA Surg, 2021,156(8):721-729. DOI: 10.1001/jamasurg.2021.2373. [19] Mariette C, Dahan L, Mornex F, et al.Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901[J]. J Clin Oncol, 2014,32(23):2416-2422. DOI: 10.1200/JCO.2013.53.6532. [20] Wei SC, Duffy CR, Allison JP.Fundamental mechanisms of immune checkpoint blockade therapy[J]. Cancer Discov, 2018,8(9):1069-1086. DOI:10.1158/21598290.CD18-0367. [21] Li C, Zhao S, Zheng Y, et al.Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)[J]. Eur J Cancer, 2021,144:232-241. DOI: 10.1016/j.ejca.2020.11.039. [22] Stahl M, Walz MK, Stuschke M, et al.Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction[J]. J Clin Oncol, 2009,27(6):851-856. DOI: 10.1200/JCO.2008.17.0506. [23] Burmeister BH, Thomas JM, Burmeister EA, et al.Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial[J]. Eur J Cancer, 2011,47(3):354-360. DOI: 10.1016/j.ejca.2010.09.009. [24] Klevebro F, Alexandersson von Döbeln G, Wang N, et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction[J]. Ann Oncol, 2016,27(4):660-667. DOI: 10.1093/annonc/mdw010. [25] Wang H, Tang H, Fang Y, et al.Morbidity and mortality of patients who underwent minimally invasive esophagectomy after neoadjuvant chemoradiotherapy vs neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma: a randomized clinical trial[J]. JAMA Surg, 2021,156(5):444-451. DOI: 10.1001/jamasurg.2021.0133. [26] Yuan M, Bao Y, Ma Z, et al.The optimal treatment for resectable esophageal cancer: a network meta-analysis of 6168 patients[J]. Front Oncol, 2021,11:628706. DOI: 10.3389/fonc.2021.628706. [27] Shapiro J, van Hagen P, Lingsma HF, et al. Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer[J]. Ann Surg, 2014,260(5):807-813; discussion 813-814. DOI: 10.1097/SLA.0000000000000966. [28] Nilsson K, Klevebro F, Rouvelas I, et al.Surgical morbidity and mortality from the multicenter randomized controlled neores II trial: standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for esophageal cancer[J]. Ann Surg, 2020,272(5):684-689. DOI: 10.1097/SLA.0000000000004340. [29] Mokdad AA, Yopp AC, Polanco PM, et al.Adjuvant chemotherapy vs postoperative observation following preoperative chemoradiotherapy and resection in gastroesophageal cancer: a propensity score-matched analysis[J]. JAMA Oncol, 2018,4(1):31-38. DOI: 10.1001/jamaoncol.2017.2805. [30] Kelly RJ, Ajani JA, Kuzdzal J, et al.Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer[J]. N Engl J Med, 2021,384(13):1191-1203. DOI: 10.1056/NEJMoa2032125. [31] Yoon HH, Ou FS, Soori GS, et al.Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849[Alliance])[J]. Eur J Cancer, 2021,150:214-223. DOI: 10.1016/j.ejca.2021.03.025.
2023, Vol. 32 
